5 reports

  • 67 Unnamed
  • Targets Under Clinical Studies
  • Cancer
  • Motor Vehicle
  • Pharmaceutical
  • Therapy
  • Cellectis S.A.
  • 12.5.3. PRODUCT PORTFOLIO
  • MARKET LANDSCAPE

CAR-TS AND OVARIAN CANCER TCRS AND OVARIAN CANCER ##. ##. ##.

  • Cancer
  • Motor Vehicle
  • Pharmaceutical
  • Therapy
  • Cellectis S.A.
  • 5.3 CELLECTIS

When OXS-## binds to cancer cells, the cancer cells internalize the drug and are killed due to the action of drug' s cytotoxic payload.

  • Cancer
  • Monoclonal Antibody
  • Therapy
  • United States
  • Cellectis S.A.

This version of the DART molecule enables the cancer-fighting properties of the immune effector cells, such as T lymphocytes, to: (##) recognize and bind to structures expressed on a cancer cell, (##) recruit all types of cytotoxic, or cell killing, T cells, irrespective of their abi

  • Cancer
  • Cell Therapy
  • Cellectis S.A.
  • Janssen Biotech, Inc.
  • Kyowa Hakko Kirin Co., Ltd.
  • Cellectis S.A. - Dormant Developmental Projects,2016
  • UCART-22 - Drug Profile

The stimulated immune responses may destroy the cancer cells.

  • Cancer
  • United States
  • World
  • Product Initiative
  • Cellectis S.A.